Repeated injections at the same site cause lipohypertrophy from insulin and SC peptides, scar tissue from IM shots, and absorption changes that can shift dose response by 20 to 30 percent or more. If you self-inject testosterone, semaglutide, tirzepatide, BPC-157, B12, or insulin, an organised rotation across multiple sites is the cheapest way to keep absorption predictable and your tissue intact. This article covers what goes wrong, the standard SC and IM zones, and how to map a rotation you can stick to.
Lipohypertrophy is a soft, rubbery thickening of subcutaneous fat caused by repeated injections at the same anatomical spot. Insulin and other peptides have local trophic effects on adipose tissue: hit the same fat depot week after week and that depot quietly enlarges. The patches are usually painless, which is why so many self-injectors miss them.
The condition was first characterised in insulin therapy and remains best documented there. A study of 430 insulin users by Blanco and colleagues (2013) found lipohypertrophy in 64.4 percent of them, strongly linked to poor site rotation, needle reuse, and unexplained hypoglycaemia; correct rotation was the strongest protection against it. Drug delivered into a hypertrophic patch absorbs erratically — blunted, delayed, or released in a burst — producing dose-to-dose variability that swamps any titration. The same biology applies to weekly GLP-1 agonists, daily peptides, and repeated B12 shots if they keep landing in the same square centimetre.
Subcutaneous absorption rate depends on local blood flow, fat thickness, and tissue health. The abdomen is generally the fastest site, the upper arm is intermediate, and the thigh is the slowest. For intramuscular drugs, ventrogluteal and vastus lateralis sites tend to give smoother peaks than the deltoid because the muscle bulk is larger. Switching sites within a protocol can change peak timing and total exposure.
The clinical magnitude is real. The FDA label for liraglutide (Victoza) reports that total exposure from the thigh was 22 percent lower than from the abdomen, though it treats the abdomen, thigh, and upper arm as comparable and needs no dose change when you switch. For shorter-acting subcutaneous insulin the difference is bigger: rapid-acting analogs absorb faster from abdomen than thigh, which is why insulin guidance asks patients to keep meal-time injections in one region and rotate within it. For IM testosterone, the Depo-Testosterone label says to inject deep into the gluteal muscle and does not compare other sites.
The four standard subcutaneous zones are the abdomen (avoiding a 5 cm circle around the navel), the front and outer thigh, the back of the upper arm, and the upper outer buttock. Each zone gives several square inches of usable tissue and together they form the rotation map most home injectors use for GLP-1 agonists, peptides, B12, and basal insulin.
Ozempic, Wegovy, Mounjaro, Zepbound, and Saxenda are all approved for abdomen, thigh, and upper arm rotation per their FDA labels. Most home peptide protocols (BPC-157, ipamorelin, CJC-1295, sermorelin, TB-500) default to the abdominal zone. Within any single zone, leave at least one centimetre between consecutive injections. The 2016 FITTER injection recommendations say lipohypertrophy distorts absorption, that you should not inject into these lumps, and that correct site rotation helps prevent them.
The four classic IM sites are the ventrogluteal (upper outer hip), dorsogluteal (upper outer buttock), vastus lateralis (outer mid-thigh), and deltoid (outer upper arm). Ventrogluteal is preferred in modern guidance because it avoids the sciatic nerve and large vessels that sit close to the older dorsogluteal landmark, while still offering a thick muscle bed.
For all IM sites: 90-degree angle, slow injection, and avoid bone, scar tissue, vessels, or any area with prior bruising.
Pick a region (abdomen, thigh, or upper arm) for each weekly injection and shift to a different quadrant the following week. A simple four-week rotation cycles right abdomen, left abdomen, right thigh, left thigh, then repeats. Stay at least 5 cm from your previous spot and skip any site that feels firm or tender. Same weekday, different square inch.
The FDA prescribing information for Ozempic (semaglutide) lists the abdomen, thigh, and upper arm, and tells patients to use a different injection site each week when injecting in the same body region. Tirzepatide (Mounjaro/Zepbound) follows the same pattern. Because semaglutide has a roughly 7-day half-life and tirzepatide a 5-day half-life, every weekly dose lands in tissue that still carries measurable drug from prior weeks; rotating sites is what keeps any single patch from accumulating local exposure. A workable cadence is four to eight discrete sites tracked in a notebook or app, injected in strict sequence — and skipped immediately if puffy or tender. If a rotation slip means a late shot, the Ozempic and Mounjaro missed-dose pages cover the label rules.
For weekly or twice-weekly intramuscular testosterone, rotate across both ventrogluteal sites, both vastus lateralis sites, and (optionally) both deltoids — six sites each used roughly every three weeks. For subcutaneous testosterone, the Xyosted label names the abdomen only, so rotate between spots on the belly. Never return to a sore or hardened spot.
The Depo-Testosterone label calls for deep injection into the gluteal muscle and does not mention rotation; rotating is a practical habit, not a label rule. For twice-weekly TRT (the modern cadence for low peak-to-trough variability), a practical six-site rotation runs: Monday right ventrogluteal, Thursday left vastus lateralis; next week left ventrogluteal then right vastus lateralis; week three the deltoids. Each site rests two to three weeks before reuse. SC TRT users (typically 0.3 to 0.5 mL with a 27-gauge insulin syringe) rotate within the abdomen. Persistent ache beyond 48 hours, visible swelling, or a hardened spot means drop that site for four to six weeks. Choosing between once- and twice-weekly shots? Weekly vs twice-weekly TRT injections compares the curves, and the Xyosted page covers the SC autoinjector.
Most clinical guidance recommends spacing repeat injections at least one centimetre apart and waiting four weeks before returning to the exact same spot. For weekly injections that means cycling through at least four to six discrete sites. Daily insulin or peptide users need a denser grid covering an entire abdominal quadrant.
These spacing rules come from insulin practice, where the 2016 FITTER recommendations in Mayo Clinic Proceedings name correct site rotation as the way to prevent lipohypertrophy and advise never injecting into an existing lump. For IM TRT, a two-to-three-week gap is realistic with six rotation points. Daily SC peptide users (BPC-157 250 to 500 mcg daily) need a 1 cm grid within a quadrant — dozens of micro-sites per region.
A good rotation map is written down, has more sites than your weekly cadence requires, and can be cross-checked against tissue you can see and feel. Human memory is unreliable — most people unconsciously favour one or two easy spots and starve the rest. A map plus a log makes that drift visible. The drug-class table below summarises typical routes and rotation intervals.
| Drug class | Route | Recommended sites | Rotation interval | Source |
|---|---|---|---|---|
| Insulin (rapid & basal) | SC | Abdomen, thigh, upper arm, upper buttock | Rotate sites; never inject into a lump | FITTER 2016 |
| GLP-1 SC (semaglutide, tirzepatide, liraglutide) | SC | Abdomen, thigh, upper arm | Different site each week | Ozempic FDA label |
| Testosterone IM (cypionate, enanthate) | IM | Gluteal (label); vastus lateralis and deltoid in common practice | 2 to 3 wk between hits at any single site | Depo-Testosterone label (gluteal only) |
| Testosterone SC (low-volume, e.g. Xyosted) | SC | Abdomen | Different spot on the belly each injection | Xyosted label (abdomen only) |
| Peptides SC (BPC-157, ipamorelin, CJC-1295) | SC | Abdomen (most common) | 1 cm spacing; rotate within quadrant daily | None: no approved label or human site guidance |
| B12 IM (cyanocobalamin, hydroxocobalamin) | IM or SC | Deltoid, vastus lateralis, ventrogluteal | Alternate sides each injection | Cyanocobalamin label (route only; no site named) |
Match the map to your cadence: weekly drugs need fewer sites, daily drugs need more. Consistency matters more than the pattern itself — a whiteboard, a notes app, or an in-app log all work. What does not work is "I'll just remember."
Run your hand over each rotation site once a week. You are checking for things you cannot see in the mirror: a soft, doughy patch that was not there before; a firm rubbery thickening compared to the symmetric site on the other side; a tender spot sore for more than 48 hours. Visible signs include persistent redness, bruising that does not resolve, leakage of injectate, blood on withdrawal more than once or twice, or visible lumps or asymmetry between sides.
Behavioural signs matter too. If the same insulin dose gives more variable glucose, a GLP-1 dose suddenly feels weaker, or a TRT trough trends down without explanation — site overuse is on the differential. In a survey of 1,247 insulin users in southern Italy, Gentile and colleagues (2020) found lipohypertrophy was tied to needle reuse and not rotating sites, and to higher HbA1c, wider glucose swings, and more hypoglycaemia. Stop using a problem site for at least four to six weeks; tissue recovers, slowly, only when the stimulus stops.
Dose Track logs every injection against an anatomical site map and warns you when a site is being overused or when the rotation interval is too tight. The site grid covers all four SC zones and four IM zones with sub-quadrant resolution, so weekly TRT, daily peptides, and weekly GLP-1 protocols all have somewhere to land. See the peptide tracking and TRT tracking pages, then download Dose Track on the App Store.